Analysts Have Conflicting Sentiments on These Healthcare Companies: Novo Nordisk (NVO), Beam Therapeutics (BEAM) and TScan Therapeutics (TCRX)
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Novo Nordisk (NVO – Research Report), Beam Therapeutics (BEAM – Research Report) and TScan Therapeutics (TCRX – Research Report).
Confident Investing Starts Here:
Novo Nordisk (NVO)
In a report issued on May 6, Evan Seigerman from BMO Capital maintained a Hold rating on Novo Nordisk, with a price target of $64.00. The company's shares closed last Friday at $67.35.
According to TipRanks.com, Seigerman is a 4-star analyst with an average return of 3.2% and a 42.7% success rate. Seigerman covers the Healthcare sector, focusing on stocks such as Structure Therapeutics, Inc. Sponsored ADR, Protagonist Therapeutics, and Arvinas Holding Company.
The word on The Street in general, suggests a Hold analyst consensus rating for Novo Nordisk with a $92.44 average price target.
BMO Capital analyst Kostas Biliouris maintained a Buy rating on Beam Therapeutics on May 7 and set a price target of $40.00. The company's shares closed last Friday at $16.83.
According to TipRanks.com, Biliouris has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -17.1% and a 29.2% success rate. Biliouris covers the Healthcare sector, focusing on stocks such as Centessa Pharmaceuticals, BioMarin Pharmaceutical, and Rocket Pharmaceuticals.
Beam Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $44.13, implying a 164.3% upside from current levels. In a report issued on May 6, William Blair also maintained a Buy rating on the stock.
TScan Therapeutics (TCRX)
BTIG analyst Jeet Mukherjee maintained a Buy rating on TScan Therapeutics on May 21 and set a price target of $12.00. The company's shares closed last Friday at $1.38, close to its 52-week low of $1.34.
According to TipRanks.com, Mukherjee has 0 stars on 0-5 stars ranking scale with an average return of -15.8% and a 31.6% success rate. Mukherjee covers the Healthcare sector, focusing on stocks such as Arvinas Holding Company, Janux Therapeutics Inc, and Carisma Therapeutics.
Currently, the analyst consensus on TScan Therapeutics is a Strong Buy with an average price target of $9.33, representing a 557.0% upside. In a report issued on May 6, TD Cowen also maintained a Buy rating on the stock.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
8 hours ago
- Yahoo
1 Underrated Reason to Buy This Market-Beating Stock
Eli Lilly recently acquired a smaller biotech for its promising investigational pain medication. The company generates strong sales from products outside of diabetes and obesity care. Eli Lilly's portfolio, both within and outside its core area, makes the stock attractive. 10 stocks we like better than Eli Lilly › Eli Lilly (NYSE: LLY) has been one of the top-performing healthcare megacap stocks of the past decade. And in more recent years, particularly over the past five, it's easy to point to the biggest factor driving Eli Lilly's run: The company's work in diabetes and, especially, the weight loss market. Eli Lilly is unquestionably one of the two leaders in this fast-growing field, and it appears to be gaining ground on its biggest competitor, Novo Nordisk. However, a recent move Eli Lilly made reveals an underrated reason why the stock has attractive prospects. Here's what investors should know. On May 27, Eli Lilly announced it would dish out $1 billion in cash to acquire SiteOne Therapeutics, a privately held biotech. The key asset from this transaction is STC-004, a mid-stage investigational non-opioid oral pain medicine. Though there are treatment options for chronic pain, non-opioid ones could become increasingly popular since opioid-based therapies often carry significant side effects. Meanwhile, this market is brand new. In January, Vertex Pharmaceuticals earned approval from the U.S. Food and Drug Administration for Journavx, the first non-opioid oral pain inhibitor. Eli Lilly is looking to make waves in this market with the acquisition of SiteOne Therapeutics. The transaction may or may not pan out. Perhaps STC-004 will flop in upcoming clinical trials. But there's something important to highlight about Eli Lilly that this acquisition brings to light. This move is hardly out of the ordinary for Eli Lilly. One thing that sets it apart from Novo Nordisk is that, while the latter generates more than 90% of its revenue from its diabetes or obesity medicines, Eli Lilly's lineup of drugs features some major blockbusters outside this area. In the first quarter, the company's revenue grew 45% year over year to $12.73 billion. Eli Lilly's cancer drug Verzenio racked up $1.2 billion in sales, up 10% year over year. The company's immunosuppressant, Taltz, generated $762 million in revenue, a 26% increase over the year-ago period. Eli Lilly's sales outside of diabetes and obesity products accounted for almost 28% of its top line. That might not exactly be peak diversification, but Eli Lilly fares better than its eternal rival, Novo Nordisk, in this department. Furthermore, the company's newer products also feature several that fall outside its core area of expertise. These include Kisunla in Alzheimer's disease, Jaypirca in oncology, and Ebglyss, an eczema treatment. The same can be said about Eli Lilly's pipeline. Consider the company's investigational gene therapy for genetic deafness, as well as its several dozen programs in oncology. To be clear, Eli Lilly's diabetes and weight management medicines should continue occupying the role of main growth drivers. In the first quarter, Mounjaro's revenue soared by 113% year over year to $3.8 billion. Zepbound's sales came in at $2.3 billion, representing a 347% increase compared to the first quarter of 2024. Neither has peaked yet. Considering analyst projections for the GLP-1 market, they will continue growing their sales at an incredible clip at least through the end of the decade. And there is more where that came from, too. Eli Lilly is developing newer medicines in this area. The company's investigational oral GLP-1 therapy, orforglipron, recently aced a phase 3 study. According to management, the drugmaker has a total of 11 obesity pipeline candidates. So, Eli Lilly's work in this field will remain one of the major keys to its success. Perhaps it is what will get many investors nowadays interested in the stock. However, Eli Lilly is also a diversified pharmaceutical giant with a strong portfolio of medicines and promising candidates in oncology, immunology, and other areas. So, even with mounting competition in the GLP-1 market, Eli Lilly remains attractive, not just because it is likely to develop better anti-obesity medicines than most of its competitors, but because it is a leader in other markets as well. That's another excellent reason to invest in Eli Lilly and hold on to its shares for a long time. Before you buy stock in Eli Lilly, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Eli Lilly wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $657,385!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $842,015!* Now, it's worth noting Stock Advisor's total average return is 987% — a market-crushing outperformance compared to 171% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 2, 2025 Prosper Junior Bakiny has positions in Eli Lilly, Novo Nordisk, and Vertex Pharmaceuticals. The Motley Fool has positions in and recommends Vertex Pharmaceuticals. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy. 1 Underrated Reason to Buy This Market-Beating Stock was originally published by The Motley Fool Sign in to access your portfolio
Bloomberg
11 hours ago
- Bloomberg
Novo Nordisk's Women Are Now Paid More Than the Men, Finans Says
Women employed at Novo Nordisk A/S are now paid more on average than the men working at the maker of blockbuster drugs Wegovy and Ozempic, according to Danish media Finans. Novo's women are paid 3% more, across job descriptions and different geographical locations, Finans said, citing data compiled by accounting firm Deloitte LLP.
Business Insider
12 hours ago
- Business Insider
Analysts Offer Insights on Industrial Goods Companies: Performance Shipping (PSHG) and Sterling Construction (STRL)
There's a lot to be optimistic about in the Industrial Goods sector as 2 analysts just weighed in on Performance Shipping (PSHG – Research Report) and Sterling Construction (STRL – Research Report) with bullish sentiments. Confident Investing Starts Here: Performance Shipping (PSHG) In a report issued on May 30, Tate Sullivan from Maxim Group reiterated a Buy rating on Performance Shipping, with a price target of $5.00. The company's shares closed last Tuesday at $1.60, close to its 52-week low of $1.48. According to Sullivan 's ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -9.9% and a 38.7% success rate. Sullivan covers the Industrial Goods sector, focusing on stocks such as United Maritime Corp., Seanergy Maritime, and BWX Technologies. The the analyst consensus on Performance Shipping is currently a Hold rating. William Blair analyst Louie DiPalma maintained a Buy rating on Sterling Construction today. The company's shares closed last Tuesday at $194.23, close to its 52-week high of $206.07. According to DiPalma has 0 stars on 0-5 stars ranking scale with an average return of -11.7% and a 60.6% success rate. DiPalma covers the Technology sector, focusing on stocks such as Palantir Technologies, Science Applications, and BigBearai Holdings. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Sterling Construction with a $205.00 average price target.
